Aventis Submits Taxotere sNDA In Early-Stage Breast Cancer; Two More Planned By Early 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
The filing is the second of four supplements planned for the oncologic over the next year. A prostate cancer sNDA was submitted earlier in the year; filings for gastric cancer and head and neck cancer are expected.